Journal article

Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept

Bruce Strober, Bárður Sigurgeirsson, Georg Popp, Rodney Sinclair, James Krell, Sigitas Stonkus, Marcis Septe, Boni E Elewski, Alice B Gottlieb, Yang Zhao, Vivian Herrera, Margaret Mordin, Dawn Odom, Charis Papavassilis, Judit Nyirady, Mark Lebwohl

Journal of Psoriasis and Psoriatic Arthritis | SAGE Publications | Published : 2016


Background Secukinumab, a fully human anti-interleukin 17A monoclonal antibody, has demonstrated rapid, strong, and sustained efficacy in moderate-to-severe plaque psoriasis. Objective To measure treatment effect on psoriasis-related itching, pain, and scaling during the first 12 weeks of treatment. Methods ERASURE and FIXTURE were double-blind, multicenter, phase 3 studies in adults randomly assigned to secukinumab (300 mg or 150 mg), placebo, or etanercept (FIXTURE only). Improvements in itching, pain, and scaling and their bothersomeness, proportions of responders and proportions reporting complete symptom relief were compared. Results Subjects treated with secukinumab reported significan..

View full abstract

Citation metrics